Glenmark Generics Launches Morphine Oral Solution - Nov 10, 2008

Glenmark Generics' US subsidiary of Glenmark Pharmaceuticals has initiated distribution of Morphine Sulfate Oral Concentrate Solution in the U.S. market through a licensing agreement with a U.S. based pharmaceutical development company. This will be the fifth product offered by Glenmark in the category of pain management.

Morphine Sulfate Oral Concentrate Solution 20mg/ml is offered in three presentations and is indicated for the relief of moderate to severe pain. Total sales for the 12 month period ending June 2008 were in excess of US$ 15 million as stated by IMS Health.

This product launch complements Glenmark's presently established portfolio of both oral solid and oral liquid pain management products. This niche market category maintains a high barrier to entry due to strict DEA regulations thereby limiting the number of competitor companies and showcasing Glenmark as the sole India-based company in each of their product launches. These products are manufactured for Glenmark in the United States through a partnership and are distributed directly from GGI's 75,000 square ft warehouse located in Mahwah, New Jersey.

Glenmark's current portfolio consists of 36 products authorized for distribution in the U.S. marketplace. The company has 40 ANDA's in various stages of the approval process with the U.S. FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.The company made this announcement during the trading hours today, 10 November 2008.